New cancer drug trial offers hope for patients out of options
NCT ID NCT02715284
Summary
This is the first study in humans of an experimental immunotherapy drug called dostarlimab for people with advanced solid tumors that have stopped responding to available treatments. The main goal is to find a safe dose and schedule for the drug and to check for early signs that it might help shrink tumors. The study will also look at how the drug moves through the body and how the immune system responds to it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Birmingham, Alabama, 35233, United States
-
GSK Investigational Site
Goodyear, Arizona, 85338, United States
-
GSK Investigational Site
Scottsdale, Arizona, 85258, United States
-
GSK Investigational Site
Fayetteville, Arkansas, 72703, United States
-
GSK Investigational Site
Encinitas, California, 92024, United States
-
GSK Investigational Site
La Jolla, California, 92093, United States
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Newport Beach, California, 92663, United States
-
GSK Investigational Site
San Francisco, California, 94115, United States
-
GSK Investigational Site
San Marcos, California, 92069, United States
-
GSK Investigational Site
Santa Monica, California, 90403, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20007, United States
-
GSK Investigational Site
Miami, Florida, 33136, United States
-
GSK Investigational Site
Tampa, Florida, 33612, United States
-
GSK Investigational Site
Augusta, Georgia, 30912, United States
-
GSK Investigational Site
Chicago, Illinois, 60637, United States
-
GSK Investigational Site
Fairway, Kansas, 66205, United States
-
GSK Investigational Site
Scarborough, Maine, 04074, United States
-
GSK Investigational Site
Baltimore, Maryland, 21231, United States
-
GSK Investigational Site
Boston, Massachusetts, 02114, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
Farmington, New Mexico, 87401, United States
-
GSK Investigational Site
Albany, New York, 12208, United States
-
GSK Investigational Site
Brooklyn, New York, 11203, United States
-
GSK Investigational Site
Jamaica, New York, 11432, United States
-
GSK Investigational Site
New York, New York, 10016, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Cleveland, Ohio, 44106, United States
-
GSK Investigational Site
Columbus, Ohio, 43210, United States
-
GSK Investigational Site
Hilliard, Ohio, 43026, United States
-
GSK Investigational Site
Hilliard, Ohio, 43210, United States
-
GSK Investigational Site
Oklahoma City, Oklahoma, 73104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19111, United States
-
GSK Investigational Site
Providence, Rhode Island, 02905, United States
-
GSK Investigational Site
Dallas, Texas, 75230, United States
-
GSK Investigational Site
Dallas, Texas, 75290-9032, United States
-
GSK Investigational Site
San Antonio, Texas, 78229, United States
-
GSK Investigational Site
Salt Lake City, Utah, 84112, United States
-
GSK Investigational Site
Charlottesville, Virginia, 22903, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
-
GSK Investigational Site
Seattle, Washington, 98195, United States
-
GSK Investigational Site
Spokane, Washington, 99202, United States
-
GSK Investigational Site
Spokane, Washington, 99204, United States
-
GSK Investigational Site
Milwaukee, Wisconsin, 53226, United States
-
GSK Investigational Site
São Paulo, 01246-000, Brazil
-
GSK Investigational Site
Calgary, Alberta, T2N 4N2, Canada
-
GSK Investigational Site
Edmonton, Alberta, T6G 1Z2, Canada
-
GSK Investigational Site
Kelowna, British Columbia, V1Y 5L3, Canada
-
GSK Investigational Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
GSK Investigational Site
Hamilton, Ontario, L8V 5C2, Canada
-
GSK Investigational Site
London, Ontario, N6A 4L6, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Montreal, Quebec, H2L 4M1, Canada
-
GSK Investigational Site
Montreal, Quebec, H4A 3J1, Canada
-
GSK Investigational Site
Hořovice, 26831, Czechia
-
GSK Investigational Site
Zlín, 762 75, Czechia
-
GSK Investigational Site
Copenhagen, DK- 2100, Denmark
-
GSK Investigational Site
Odense C, 5000, Denmark
-
GSK Investigational Site
Caen, 14076, France
-
GSK Investigational Site
Lille, 59000, France
-
GSK Investigational Site
Marseille, 13273, France
-
GSK Investigational Site
Paris, 75571, France
-
GSK Investigational Site
Paris, 75908, France
-
GSK Investigational Site
Saint-Herblain, 44805, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Milan, 20132, Italy
-
GSK Investigational Site
Milan, 20133, Italy
-
GSK Investigational Site
Milan, 20141, Italy
-
GSK Investigational Site
Modena, 41100, Italy
-
GSK Investigational Site
Naples, 80131, Italy
-
GSK Investigational Site
Roma, 00144, Italy
-
GSK Investigational Site
Verona, 37134, Italy
-
GSK Investigational Site
Gdynia, 81-519, Poland
-
GSK Investigational Site
Lublin, 20-090, Poland
-
GSK Investigational Site
Olsztyn, 10-513, Poland
-
GSK Investigational Site
Olsztyn, 10-561, Poland
-
GSK Investigational Site
Torun, 87-100, Poland
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Barcelona, 08907, Spain
-
GSK Investigational Site
Barcelona, 8035, Spain
-
GSK Investigational Site
Girona, 08907, Spain
-
GSK Investigational Site
Girona, 17007, Spain
-
GSK Investigational Site
Madrid, 28027, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28050, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
-
GSK Investigational Site
Pamplona, 31008, Spain
-
GSK Investigational Site
Santiago de Compostela, 15706, Spain
-
GSK Investigational Site
Seville, 41013, Spain
-
GSK Investigational Site
Valencia, 46009, Spain
-
GSK Investigational Site
Valencia, 46010, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Aberdeen, AB25 2ZN, United Kingdom
-
GSK Investigational Site
London, SE1 9RT, United Kingdom
-
GSK Investigational Site
London, SW3 6JJ, United Kingdom
-
GSK Investigational Site
London, W1G 6AD, United Kingdom
-
GSK Investigational Site
London, W1T 7HA, United Kingdom
-
GSK Investigational Site
Manchester, M20 4BX, United Kingdom
-
GSK Investigational Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
GSK Investigational Site
Oxford, OX3 7LE, United Kingdom
-
GSK Investigational Site
Sutton, SW36JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.